Entero Therapeutics, Inc. (NasdaqCM: ENTO) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Entero shareholders.